Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 6/20 | 0.49 |
| ▸ | CTSK | P43235 | 6/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 4/20 | 0.43 |
| ▸ | CTSB | P07858 | 4/20 | 0.43 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896495 | 0.94 | SYK (0.48) | SYKBACE1CTSKATMCTSL | |
| SCHEMBL1554884 | 0.94 | SYK (0.48) | SYKBACE1CTSKATMCTSL | |
| SCHEMBL4896500 | 0.93 | SYK (0.47) | SYKBACE1CTSKATMCTSL | |
| SCHEMBL14256999 | 0.91 | SYK (0.52) | SYKBACE1CTSKATMCTSL | |
| SCHEMBL15003939 | 0.89 | SYK (0.51) | SYKBACE1CTSKCTSLCTSS | |
| SCHEMBL15316174 | 0.89 | SYK (0.51) | SYKBACE1CTSKCTSLCTSS | |
| SCHEMBL5729333 | 0.88 | SYK (0.51) | SYKBACE1CTSKATMCTSL | |
| SCHEMBL8693569 | 0.87 | SYK (0.50) | SYKBACE1CTSKATMCTSL | |
| SCHEMBL31391011 | 0.87 | SYK (0.48) | SYKBACE1CTSKATMCTSL | |
| SCHEMBL15316179 | 0.85 | BACE1 (0.61) | SYKBACE1CTSKATMCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064681-A1 | Therapeutic agent for treating glaucoma | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064681-A1 | Therapeutic agent for treating glaucoma | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064681-A1 | Therapeutic agent for treating glaucoma | PDE6G, PDE3A, PDE5A | SYK 4481/4885BACE1 3546/4885CTSK 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.